Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity

ANAPTYSBIO, INC

Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.
Anaptys has repurchased 3,443,188 shares (11.2% of shares outstanding) under the plan to date.
Company expects ~$300M cash end-2025, including anticipated $75M commercial milestone from GSK on Jemperli reaching $1B sales.
Plan expires March 31, 2026; repurchases depend on market conditions and regulatory limitations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.